Acrivon Therapeutics’ major shareholder sells shares worth $1.02 million

Published 02/05/2025, 00:14
Acrivon Therapeutics’ major shareholder sells shares worth $1.02 million

In recent transactions reported to the SEC, Perceptive Advisors LLC, a significant shareholder in Acrivon Therapeutics , Inc. (NASDAQ:ACRV), sold a substantial number of shares. The transactions, which took place on April 30 and May 1, involved the sale of 437,881 shares at a weighted average price of $1.41 and 298,886 shares at a weighted average price of $1.34, respectively. The sales were conducted at prices ranging from $1.33 to $1.53 per share. The stock is currently trading near its 52-week low of $1.30, having declined about 84% over the past year. According to InvestingPro analysis, technical indicators suggest the stock is in oversold territory.

These transactions resulted in a total sale value of approximately $1.02 million. Following these sales, Perceptive Advisors LLC retains ownership of 3,104,139 shares of Acrivon Therapeutics, which represents a significant portion of the company’s current market capitalization of $43.89 million. InvestingPro data shows the company maintains a strong liquidity position with a current ratio of 10.55 and more cash than debt on its balance sheet. Subscribers can access 15+ additional ProTips and comprehensive financial metrics in the Pro Research Report.

The shares are directly held by Perceptive Life Sciences Master Fund Ltd., with Perceptive Advisors LLC serving as the investment manager. Joseph Edelman, the managing member of Perceptive Advisors LLC, signed the report, highlighting his role in overseeing the investment activities of the fund.

In other recent news, Acrivon Therapeutics has reported its financial performance for the fourth quarter and full year of 2024, with operating expenses reaching $25 million in the last quarter and $89.2 million for the year. The company also disclosed an earnings per share (EPS) of ($0.60) for the fourth quarter and ($2.43) for the full year. Analyst firm H.C. Wainwright adjusted its price target for Acrivon to $19.00, down from $22.00, while maintaining a Buy rating, following an investor webinar that presented updated results from the Phase 2 study of ACR-368. Cantor Fitzgerald also maintained an Overweight rating, highlighting strong data on ACR-368, despite some efficacy dilution, and noted a strategic shift to prioritize endometrial cancer. JMP Securities reiterated a Market Outperform rating with a $17.00 price target, emphasizing the promising profile of ACR-368 in metastatic endometrial cancer. Acrivon has appointed Dr. Mansoor Raza Mirza as its new chief medical officer to lead the clinical development of its pipeline, including the ACR-368 and ACR-2316 trials. The company ended 2024 with a robust cash position of $179.5 million, expected to support operations into 2027. These recent developments reflect Acrivon’s focused efforts on advancing its oncology drug candidates and strategic adjustments in its research priorities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.